PathAI
AI-powered pathology platform to improve patient outcomes and transform diagnostics
Enterprise·Technical·Powered by PathAI (proprietary)·API available
Key strengths
FDA-cleared and CE-IVDR marked digital pathology platform (AISight® Dx)First FDA-qualified AI tool for MASH clinical trials (AIM-MASH)Proprietary network of 450+ board-certified pathologists contributing 32.5M+ annotationsEnd-to-end AI solutions spanning biomarker discovery, drug development, and lab workflowsAdopted by 90% of top 15 BioPharma companies
Enterprise pricing
Boston, United States
Founded 2016
No ratings yet
No content available for this audience yet.